Literature DB >> 22782802

Human UDP-glucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics.

Hongbo Zhang1, Anne-Sisko Patana, Peter I Mackenzie, Shinichi Ikushiro, Adrian Goldman, Moshe Finel.   

Abstract

Many laboratories use recombinant UDP-glucuronosyltransferases (UGTs), expressed in baculovirus-infected insect cells, for drug glucuronidation studies. We have infected Sf9 insect cells with increasing amounts of recombinant baculovirus, encoding either UGT1A9 or UGT2B7, and measured both glucuronidation activity and immunodetectable UGT in the resulting cell homogenates. The correlation between glucuronidation rates and degree of infection followed different trends, depending on whether activity was the actual activity measured or was corrected for UGT expression level. Above a certain low level of infection, further increases in infection ratios led to a large decline in normalized activity, presumably due to the presence of full-length but inactive enzyme in the sample. Because immunodetection does not distinguish between active and inactive UGT, comparison of normalized activity between different batches of a recombinant UGT, mutants of a given UGT, or different UGTs is prone to large inaccuracies. Such inaccuracies could be reduced by lowering the degree of infection of the insect cells, in combination with careful monitoring of UGT expression. However, the latter requires suitable antibodies for comparing UGT expression levels among preparations, antibodies that are not always available. Poly-His (His-tag)-containing peptides, fused to the UGT C terminus, allow sensitive immunodetection of expressed enzymes with monoclonal antibodies. We have now carefully examined the effects of two such fusion peptides on enzyme kinetics. A minor increase in the K(m) values has been detected in the His-tagged UGTs, but no changes in parameters such as the kinetic model and the effects of albumin addition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22782802     DOI: 10.1124/dmd.112.046086

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  AAPS J       Date:  2016-06-30       Impact factor: 4.009

2.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

3.  Oligomerization and Catalytic Parameters of Human UDP-Glucuronosyltransferase 1A10: Expression and Characterization of the Recombinant Protein.

Authors:  Kyungbo Kim; Fang Zheng; Chang-Guo Zhan
Journal:  Drug Metab Dispos       Date:  2018-08-15       Impact factor: 3.922

Review 4.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Aleksandra Galetin; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-08-09       Impact factor: 4.009

5.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Authors:  Kathleen M Knights; Shane M Spencer; John K Fallon; Nuy Chau; Philip C Smith; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

6.  The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.

Authors:  Martin Perreault; Louis Gauthier-Landry; Jocelyn Trottier; Mélanie Verreault; Patrick Caron; Moshe Finel; Olivier Barbier
Journal:  Drug Metab Dispos       Date:  2013-06-11       Impact factor: 3.922

7.  Use of a Baculovirus-Mammalian Cell Expression-System for Expression of Drug-Metabolizing Enzymes: Optimization of Infection With a Focus on Cytochrome P450 3A4.

Authors:  Yuu Miyauchi; Akane Kimura; Madoka Sawai; Keiko Fujimoto; Yuko Hirota; Yoshitaka Tanaka; Shinji Takechi; Peter I Mackenzie; Yuji Ishii
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

8.  Integrate thermostabilized fusion protein apocytochrome b 562 RIL and N-glycosylation mutations: A novel approach to heterologous expression of human UDP-glucuronosyltransferase (UGT) 2B7.

Authors:  Jia Xue; Haitao Zhang; Su Zeng
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

9.  Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Authors:  Ryan W Dellinger; Harry H Matundan; Amelia S Ahmed; Priscilla H Duong; Frank L Meyskens
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.